 Connection
Michael DiStefano to Drug Costs
This is a "connection" page, showing publications Michael DiStefano has written about Drug Costs.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.462 |
|
|
|
-
DiStefano MJ, McQueen RB, Zheng H, Gyamfi HG, Ameyaw D, Campbell JD, Zemplenyi A. Opportunities for CMS to Further Specify and Broaden Its Approach to Assessing Unmet Medical Need in the Context of the Medicare Drug Price Negotiation Program. Appl Health Econ Health Policy. 2026 03; 24(2):261-269.
Score: 0.838
-
Zemplenyi AT, Chen NC, Anderson KE, Adamson B, DiStefano MJ, Nair KV, McQueen RB. Key Considerations for Assessing Real-World Comparative Effectiveness in the Context of the Drug Price Negotiation Program: A Case Study of Pembrolizumab. Pharmacoeconomics. 2025 09; 43(9):1147-1160.
Score: 0.205
-
DiStefano MJ, Levy JF, Odouard IC, Anderson GF. Estimated Savings From Using Added Therapeutic Benefit and Therapeutic Reference Pricing in United States Medicare Drug Price Negotiations. Value Health. 2023 11; 26(11):1618-1624.
Score: 0.181
-
Kang SY, Bai G, DiStefano MJ, Socal MP, Yehia F, Anderson GF. Comparative Approaches to Drug Pricing. Annu Rev Public Health. 2020 04 02; 41:499-512.
Score: 0.140
-
Socal MP, Kandula NR, Bareamichael PI, Ballreich J, Odouard I, Kang SY, Acha JO, Anderson KE, DiStefano M, Gerchman F, Levy JF. Improving Affordability of Pharmaceutical Treatments for Diabetes: A Call for Action. Diabetes Care. 2026 Jan 01; 49(1):30-43.
Score: 0.053
-
Anderson KE, DiStefano MJ, Liu A, Mattingly TJ, Socal MP, Anderson GF. Incorporating Added Therapeutic Benefit and Domestic Reference Pricing Into Medicare Payment for Expensive Part B Drugs. Value Health. 2023 09; 26(9):1381-1388.
Score: 0.044
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|